Pulmonary Atelectasis

— New survey reveals the prevalence of "Unseenism," which can be described as a social phenomenon where gender and age biases can leave some patients feeling overlooked or unheard, in healthcare — — 58% of women who chose not to speak up during a visit with their doctor said it was because their health concerns were previously ignored — — Insmed's educational initiative "Speak Up in BE" aims to bring hope, education, and a sense of belonging to bronchiectasis (BE) patients who are feeling unseen — BRIDGEWATER, N.J., Feb. 28, 2024 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced its involvement with award-winning actress Jane Seymour to raise awareness of gender and age biases in healthcare. Insmed conducted a nationally representative survey to reveal how these unconscious and often enduring biases leave some people feeling overlooked, unheard, or ignored, a societal phenomenon that can be described as "Unseenism." Survey data found that this phenomenon is especially prevalent for those with chronic conditions like bronchiectasis (BE). "In both my television and film roles and in real life, I've always tried to push back against the typical notions of aging and feeling unseen. Being older shouldn't mean you are no longer valuable or relevant," said Seymour. "I am thrilled to work with Insmed to lend a voice to this all-too-familiar topic and encourage others to speak up and advocate for themselves, particularly when it comes to their health, regardless of age or gender." The survey of over 2,000 participants, conducted by Insmed, aimed to uncover how "Unseenism" can shape the health decisions of people aged 40+ years. Key insights from the survey indicate that: 62% of women surveyed stated they feel more overlooked or believe they will feel more overlooked as they age. 82% of respondents said they leave a doctor's appointment without getting all their questions answered and understanding all that was discussed. 40% of people surveyed said they have previously chosen not to speak up to their doctor even though they had something to say. Reasons cited for not speaking up included their health concerns were previously ignored (58%), they feared their concerns wouldn't be addressed (44%), or they didn't want to burden their doctor (41%). For those suffering from chronic conditions, the experience of feeling unseen can be magnified, including in patients with BE, a respiratory disease that causes permanent widening of the airways, which can make it difficult to clear mucus and bacteria. BE is underrecognized and its diagnosis is often missed or delayed. Approximately two-thirds of patients diagnosed with BE are women and the average age of patients is 68. Over time, patients may experience worsening symptoms or flares – which can contribute to irreversible lung damage. This is why it is critical to ensure patients receive timely and proper care. The survey also included a subset of BE patients. Among those respondents (n=83): 57% cited illness as the factor that has contributed most to them ever feeling unseen; 35% noted that their diagnosis made them feel more unseen. 79% said they have felt more unseen as they age. 72% said being knowledgeable about their health makes them feel empowered to speak up with healthcare providers. "These findings highlight the urgent need to bridge communication gaps and amplify health education initiatives for patients who feel unseen," said Alana Clemens-Saliba, Executive Director, Patient Advocacy & Professional Society Engagement at Insmed. "That's why we're proud of the Speak Up in BE campaign, an educational initiative dedicated to providing information and resources on BE to help patients feel understood, supported, and empowered to raise their voices." Living with BE can be challenging, but patients are not alone in their journey. Speak Up in BE provides resources for patients, including questions that can start conversations with a doctor, ways to connect with others in the community, and a limited-edition book full of stories, articles, and tips from real people living with BE to help patients who are feeling unseen. To learn more about BE, please visit SpeakUpInBronchiectasis.com. About Bronchiectasis Bronchiectasis is a serious, chronic lung disease in which the bronchi become permanently dilated due to a cycle of infection, inflammation, and lung tissue damage. The condition is marked by frequent pulmonary exacerbations requiring antibiotic therapy and/or hospitalizations. Symptoms include chronic cough, excessive sputum production, shortness of breath, and repeated respiratory infections, which can worsen the underlying condition. Bronchiectasis affects approximately 340,000 to 520,000 patients in the U.S. About Insmed Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. We seek to bring forward therapies that address patients' most urgent unmet needs by leveraging cutting-edge technologies and employing new modes of drug discovery, delivery, and development. Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan. Visit to learn more. Contact: Investors: Bryan Dunn Executive Director, Investor Relations Insmed (646) 812-4030 [email protected] Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 [email protected] Media: Mandy Fahey Executive Director, Corporate Communications Insmed (732) 718-3621 [email protected] SOURCE Insmed Incorporated

The MONARCH™ Platform is the first minimally invasive, robotic-assisted technology approved for bronchoscopy in a country with significant burden of lung cancer. REDWOOD CITY, Calif., Nov. 13, 2023 /PRNewswire/ -- Johnson & Johnson MedTech* today announced that the MONARCH Platform and MONARCH Bronchoscope have obtained regulatory approval in China. The platform is the first minimally invasive, robotic-assisted technology approved for peripheral lung procedures in China and the first J&J MedTech robotic-assisted technology approved in China. This also marks the first regulatory approval of the MONARCH Platform outside of the United States. The MONARCH Platform, used with the MONARCH Bronchoscope, is intended to provide bronchoscopic visualization of and access to adult patient airways for diagnostic and therapeutic procedures. The device enables physicians to use minimally invasive, robotic-assisted technology for peripheral lung procedures. The ability to reach small, hard-to-reach peripheral lung nodules at an earlier stage and with greater precision is helping to transform the future of interventional care for patients because nodules from lung cancer are typically small, deep in the lungs and difficult to reach, making early-stage diagnosis and treatment difficult. Lung cancer is the leading cause of cancer deaths worldwide, and early detection has been shown to increase survival rates if the disease is caught at a stage when it is more likely to be treated successfullyi. "There are more than two million patients diagnosed with lung cancer each year around the world, and nearly 40% of them are in Chinaii," said Will Song, President, Johnson & Johnson MedTech China. "With this approval, MONARCH is poised to aid physicians in China as they work with patients to fight one of the most prevalent and deadly diseases in the country." "The MONARCH team is committed to driving meaningful innovation that changes the way patients experience healthcare," said Adrian Whitford, President, MONARCH. "Expanding the reach of flexible robotic-assisted devices for lung procedures to countries around the world is part of our vision to deliver breakthrough technology that improves clinical outcomes for patients fighting diseases like lung cancer." To date, The MONARCH platform has been used in more than 35,000 cases in the United States. About Johnson & Johnson MedTech At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive and more personalized. To learn more, visit * Comprising the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson's MedTech segment. Indications for Use (United States) The MONARCH™ Bronchoscope and the MONARCH™ Platform and its accessories are intended to provide bronchoscopic visualization of and access to patient airways for diagnostic and therapeutic procedures. Important Safety Information Complications from bronchoscopy may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. More serious complications from bronchoscopy may include collapsed lung, respiratory failure, hemorrhage, burns, heart attack, or cardiac arrhythmia. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding Johnson & Johnson MedTech, the MONARCH Platform and MONARCH Bronchoscope. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Auris Health, Inc., Johnson & Johnson Medical (Shanghai) Ltd. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at , or on request from Johnson & Johnson. None of Auris Health, Inc., Johnson & Johnson Medical (Shanghai) Ltd. nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. Media Contact: Ryan Carbain [email protected] Investor Relations Sarah Wood [email protected] SOURCE Johnson & Johnson MedTech

NEW DELHI, May 24, 2023 /PRNewswire/ -- Doctors at Manipal Hospital, Delhi recently performed a groundbreaking robotic-assisted Coronary Artery Bypass Grafting (CABG) surgery on a 44-year-old male patient from Iraq. The patient came to the hospital with a complaint of chest pain and upon further diagnosis, it was found that the patient was suffering from triple vessel blockage, requiring revascularization. As the patient was already undergoing cancer treatment, looking at his condition Dr. Yugal Kishore Mishra, Chief of Clinical Services, Head of Cardiac Sciences, and Chief Cardiovascular Surgeon at Manipal Hospital, Delhi and his team decided to proceed with robotic-assisted CABG surgery. In this case, this innovative approach played a major role considering the condition of the patient and the risk factors. The procedure is aimed at ensuring a quicker recovery, smaller surgical wounds, and reduced chances of healing complications for the patient. Unlike traditional CABG surgery, robotic-assisted CABG enables patients to experience a faster recovery time, minimal scarring, and potentially improved graft placement, thanks to its minimally invasive technique. The procedure also incorporates continuous one-lung ventilation (OLV), an advanced technique that significantly lowers the risk of complications during surgery, including bleeding, infection, and lung collapse. Commenting on the successful surgery of this patient, Dr. Mishra said, "This was a complicated case as the patient was undergoing treatment for cancer. We opted for a robotic CABG as an open-heart surgery would have taken longer recovery time and would have created complications in treatment of his cancer. Robotic-assisted CABG offers several advantages over traditional CABG surgery, including smaller incisions, greater precision, reduced blood loss, shorter hospital stays, and faster return to daily activities. This advanced approach provides patients with a quicker recovery time and improved overall comfort. His surgery was successful and he was discharged from the hospital after five days." Manipal Hospital, Delhi, continues to uphold its commitment to providing state-of-the-art healthcare services, offering the latest medical advancements and personalized treatment options to patients from across the globe. About Manipal Hospitals As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 4.5 million patients annually. Its focus is to develop an affordable, high quality healthcare framework through its multispecialty and tertiary care delivery spectrum and further extend it to out of hospital care. With the completion of acquisition of 100% shareholding in Columbia Asia Hospitals Private Limited and Vikram Hospital (Bengaluru) Private Limited, the integrated network today has a pan-India footprint of 29 hospitals across 16 cities with 8,300+ beds, and a talented pool of 4,000 doctors and an employee strength of over 12,000. Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals is NABH, AAHRPP accredited and most of the hospitals in its network are NABL, ER, Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognised the most respected and patient recommended hospital in India through various consumer surveys. Media Contact: Call us: +91-8376965812, +91-7303881483 Email us: [email protected] Visit us at: Logo: SOURCE Manipal Hospitals, Delhi